Review
Copyright ©The Author(s) 2024.
World J Clin Oncol. Apr 24, 2024; 15(4): 496-522
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.496
Figure 3
Figure 3 Some of the current immunotherapy approaches of treatment to ovarian cancer. Anti-CTLA-4: Cytotoxic T-Lymphocyte Associated Protein 4 Antibody; Anti-PD1: Programmed Cell death Protein 1 Antibody; Anti PD-L1: Programmed Death-ligand 1 Antibody; CAR-T cells: Chimeric Antigen Receptor-T cells; PARP: Poly Adenosine Diphosphate-Ribose Polymerase; PD-1: Programmed Cell death Protein 1; PD-L1: Programmed Death-ligand 1.